Escaping ALK inhibition: mechanisms of and strategies to overcome resistance
- PMID: 22323827
- DOI: 10.1126/scitranslmed.3003728
Escaping ALK inhibition: mechanisms of and strategies to overcome resistance
Abstract
Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.
Comment on
-
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25. Sci Transl Med. 2012. PMID: 22277784 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
